{
    "id": 25254,
    "fullName": "EGFR T34_A289del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR T34_A289del results in the deletion of 256 amino acids in the extracellular domain of the Egfr protein from amino acids 34 to 289 (UniProt.org). T34_A289del results in ligand independent constitutive phosphorylation of Egfr, increased proliferation, and invasion of cells in culture (PMID: 27216155).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "T34_A289del",
    "createDate": "08/18/2016",
    "updateDate": "09/03/2018",
    "referenceTranscriptCoordinates": {
        "id": 135919,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55142299_55154132del11834",
        "cDna": "c.102_869del11834",
        "protein": "p.S35_T290del256",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7812,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 1136,
                "therapyName": "Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7811,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7813,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155).",
            "molecularProfile": {
                "id": 26048,
                "profileName": "EGFR T34_A289del"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6503,
                    "pubMedId": 27216155,
                    "title": "A Novel EGFR Extracellular Domain Mutant, EGFR\u0394768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216155"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26048,
            "profileName": "EGFR T34_A289del",
            "profileTreatmentApproaches": [
                {
                    "id": 10587,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR T34_A289del"
                },
                {
                    "id": 10588,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR T34_A289del"
                },
                {
                    "id": 10584,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR T34_A289del"
                },
                {
                    "id": 10586,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR T34_A289del"
                },
                {
                    "id": 10585,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR T34_A289del"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135920,
            "transcript": "NM_201284",
            "gDna": "chr7:g.55142299_55154132del11834",
            "cDna": "c.102_869del11834",
            "protein": "p.S35_T290del256",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135921,
            "transcript": "NM_201282",
            "gDna": "chr7:g.55142299_55154132del11834",
            "cDna": "c.102_869del11834",
            "protein": "p.S35_T290del256",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135919,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55142299_55154132del11834",
            "cDna": "c.102_869del11834",
            "protein": "p.S35_T290del256",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 135922,
            "transcript": "NM_201283",
            "gDna": "chr7:g.55142299_55154132del11834",
            "cDna": "c.102_869del11834",
            "protein": "p.S35_T290del256",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}